Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

“Men with metastatic castration-resistant prostate cancer are often faced with a poor prognosis and limited treatment options, and Talzenna in combination with Xtandi has redefined the ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

FDA advisors unanimously snub Pfizer's Talzenna in broader prostate cancer population FDA advisors unanimously voted against expanding Pfizer’s Talzenna to a broader prostate cancer population without ...

Pfizer Inc. failed to convince advisers to the US Food and Drug Administration to support a dramatic expansion in the use of its prostate cancer drug, a setback that could scuttle the company’s ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.

Feds probe disputed tip Pfizer held Covid vaccine results until after 2020 vote: WSJ President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the ...

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. ...

Pfizer's TALAPRO-2 study shows Talzenna + Xtandi significantly improves survival in mCRPC patients, with up to a 14-month OS gain in HRR-mutated cases.